[高胆固醇血症-谁、何时、如何治疗?]

IF 0.6 4区 医学 Q3 MEDICINE, GENERAL & INTERNAL
Deutsche Medizinische Wochenschrift Pub Date : 2023-09-01 Epub Date: 2023-08-23 DOI:10.1055/a-1956-9851
Martin Merkel
{"title":"[高胆固醇血症-谁、何时、如何治疗?]","authors":"Martin Merkel","doi":"10.1055/a-1956-9851","DOIUrl":null,"url":null,"abstract":"<p><p>In recent years, clinical scientific data on LDL cholesterol and atherosclerosis has led to lowering of LDL-C targets and the expansion of the indication for lipid drug therapy to larger populations or patients. The calculators SCORE2 and SCORE-OP were newly developed to calculate the cardiovascular risk in primary prevention. When assessing the cardiovascular risk of patients, in addition to e.g., pre-existing cardiovascular disease, familial hypercholesterolaemia and type II diabetes, type I diabetes, diabetic complications, renal insufficiency and subclinical arteriosclerosis are also considered. Statins are the basic therapy for hypercholesterolemia. Alternative medication are ACL inhibitors e.g., Bempedoic acid and Inclisiran which represent new drug therapy options for statin intolerance. Nevertheless, a dietary intervention belongs at the beginning of every lipid-lowering therapy.</p>","PeriodicalId":11370,"journal":{"name":"Deutsche Medizinische Wochenschrift","volume":null,"pages":null},"PeriodicalIF":0.6000,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"[Hypercholesterolemia - who, when, how to treat?]\",\"authors\":\"Martin Merkel\",\"doi\":\"10.1055/a-1956-9851\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>In recent years, clinical scientific data on LDL cholesterol and atherosclerosis has led to lowering of LDL-C targets and the expansion of the indication for lipid drug therapy to larger populations or patients. The calculators SCORE2 and SCORE-OP were newly developed to calculate the cardiovascular risk in primary prevention. When assessing the cardiovascular risk of patients, in addition to e.g., pre-existing cardiovascular disease, familial hypercholesterolaemia and type II diabetes, type I diabetes, diabetic complications, renal insufficiency and subclinical arteriosclerosis are also considered. Statins are the basic therapy for hypercholesterolemia. Alternative medication are ACL inhibitors e.g., Bempedoic acid and Inclisiran which represent new drug therapy options for statin intolerance. Nevertheless, a dietary intervention belongs at the beginning of every lipid-lowering therapy.</p>\",\"PeriodicalId\":11370,\"journal\":{\"name\":\"Deutsche Medizinische Wochenschrift\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.6000,\"publicationDate\":\"2023-09-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Deutsche Medizinische Wochenschrift\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1055/a-1956-9851\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2023/8/23 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q3\",\"JCRName\":\"MEDICINE, GENERAL & INTERNAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Deutsche Medizinische Wochenschrift","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1055/a-1956-9851","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/8/23 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
引用次数: 0

摘要

近年来,关于低密度脂蛋白胆固醇和动脉粥样硬化的临床科学数据已经降低了低密度脂素胆固醇靶点,并将脂质药物治疗的适应症扩展到更大的人群或患者。计算器SCORE2和SCORE-OP是新开发的,用于计算初级预防中的心血管风险。在评估患者的心血管风险时,除了预先存在的心血管疾病、家族性高胆固醇血症和II型糖尿病、I型糖尿病、糖尿病并发症、肾功能不全和亚临床动脉硬化外,还应考虑。他汀类药物是治疗高胆固醇血症的基本药物。替代药物是ACL抑制剂,如贝多酸和Inclisiran,它们代表了他汀类药物不耐受的新药物治疗选择。然而,饮食干预属于每一种降脂治疗的开始。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
[Hypercholesterolemia - who, when, how to treat?]

In recent years, clinical scientific data on LDL cholesterol and atherosclerosis has led to lowering of LDL-C targets and the expansion of the indication for lipid drug therapy to larger populations or patients. The calculators SCORE2 and SCORE-OP were newly developed to calculate the cardiovascular risk in primary prevention. When assessing the cardiovascular risk of patients, in addition to e.g., pre-existing cardiovascular disease, familial hypercholesterolaemia and type II diabetes, type I diabetes, diabetic complications, renal insufficiency and subclinical arteriosclerosis are also considered. Statins are the basic therapy for hypercholesterolemia. Alternative medication are ACL inhibitors e.g., Bempedoic acid and Inclisiran which represent new drug therapy options for statin intolerance. Nevertheless, a dietary intervention belongs at the beginning of every lipid-lowering therapy.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Deutsche Medizinische Wochenschrift
Deutsche Medizinische Wochenschrift 医学-医学:内科
CiteScore
0.80
自引率
0.00%
发文量
432
审稿时长
3-6 weeks
期刊介绍: Ein Schwerpunktthema - verschiedene Perspektiven Mit vielen praktischen Tipps und konkreten Handlungsanweisungen. Kurz und prägnant: Aktuell informiert Interessante Nachrichten für Sie zusammengefasst und von Experten kommentiert. Fundiertes Fachwissen - für Einsteiger und Profis Ein bunter Mix aus Übersichten, Fallbeispielen, Kasuistiken und Schritt-für-Schritt-Anleitungen. Blick über den Tellerrand Erweitern Sie Ihren Fokus über das reine Fachwissen hinaus mit "Medizin im Kontext".
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信